ROS1型
医学
中枢神经系统
癌症研究
内科学
癌症
腺癌
作者
Ami V. Desai,Aditi Bagchi,Amy E. Armstrong,Cornelis M. van Tilburg,Ellen M. Basu,Giles Robinson,Huanmin Wang,Michela Casanova,Nicolás André,Quentin Campbell-Hewson,Yeming Wu,Alison K. Cardenas,Bo Ci,Carolina Ryklansky,Clare Devlin,Georgina Meneses‐Lorente,Jade Wulff,Katherine E. Hutchinson,Amar Gajjar,Elizabeth Fox
标识
DOI：10.1016/j.ejca.2025.115308
摘要
Integrated data from three trials confirm entrectinib induces rapid and durable responses in children with NTRK or ROS1 fusion-positive tumours. The increased duration of safety monitoring does not demonstrate new or cumulative toxicity. Registered clinical trials: STARTRK-NG: NCT02650401; TAPISTRY: NCT04589845; STARTRK-2: NCT02568267.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
大力的冬萱
cdercder
OK
ale
Avalonx
行走的荷尔蒙
lizishu
初景
yjh123
sagitar
Nole
MozzieMiao
Oracle
乐空思
arniu2008
Copyright
YZ
zzzz
雪满头
皖公网安备34019202002308
